Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study.

MLA

Ebina, Kosuke, et al. “Add-on Effectiveness of Methotrexate or Iguratimod in Patients with Rheumatoid Arthritis Exhibiting an Inadequate Response to Janus Kinase Inhibitors: The ANSWER Cohort Study.” Modern Rheumatology, vol. 33, no. 4, July 2023, pp. 690–99. EBSCOhost, https://doi.org/10.1093/mr/roac092.

APA

Ebina, K., Hirano, T., Maeda, Y., Okita, Y., Etani, Y., Hirao, M., Yamamoto, W., Hashimoto, M., Murata, K., Onishi, A., Jinno, S., Hara, R., Son, Y., Amuro, H., Kotani, T., Shiba, H., Katayama, M., Yamamoto, K., Kumanogoh, A., & Okada, S. (2023). Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study. Modern Rheumatology, 33(4), 690–699. https://doi.org/10.1093/mr/roac092

Chicago

Ebina, Kosuke, Toru Hirano, Yuichi Maeda, Yasutaka Okita, Yuki Etani, Makoto Hirao, Wataru Yamamoto, et al. 2023. “Add-on Effectiveness of Methotrexate or Iguratimod in Patients with Rheumatoid Arthritis Exhibiting an Inadequate Response to Janus Kinase Inhibitors: The ANSWER Cohort Study.” Modern Rheumatology 33 (4): 690–99. doi:10.1093/mr/roac092.